Technical Analysis for FGEN - FibroGen, Inc

Grade Last Price % Change Price Change
grade F 35.57 1.25% 0.44
FGEN closed up 1.25 percent on Friday, May 24, 2019, on 65 percent of normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions. Due to the stock's strong downtrend, it may remain oversold for a while. So, if you're looking for a reason to buy, don't put too much weight on it being oversold.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Strong Down Down Down
See historical FGEN trend table...

Date Alert Name Type % Chg
Narrow Range Bar Range Contraction 0.00%
NR7 Range Contraction 0.00%
NR7-2 Range Contraction 0.00%
Wide Bands Range Expansion 0.00%
Oversold Stochastic Weakness 0.00%
New 52 Week Closing Low Bearish 1.25%
Narrow Range Bar Range Contraction 1.25%
NR7 Range Contraction 1.25%
NR7-2 Range Contraction 1.25%
Wide Bands Range Expansion 1.25%

Older signals for FGEN ...

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

FibroGen, Inc. operates as a research-based biopharmaceutical company in the United States. The company focuses on the discovery, development, and commercialization of therapeutic agents to treat serious unmet medical needs. The company develops roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases that is in Phase III clinical development for the treatment of anemia in chronic kidney disease; and FG-3019, a monoclonal antibody, which is in Phase II clinical development for the treatment of idiopathic pulmonary fibrosis, pancreatic cancer, and liver fibrosis. It also focuses on use of the proprietary type III recombinant human collagens in its biosynthetic corneal implant product candidate, FG-5200 for the treatment of corneal blindness. The company was incorporated in 1993 and is headquartered in San Francisco, California.
Biotechnology Biopharmaceutical Life Sciences Chronic Kidney Disease Pancreatic Cancer Anemia Idiopathic Pulmonary Fibrosis Hypoxia Inducible Factors Liver Fibrosis Research Based Biopharmaceutical
Is FGEN a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 0 bullish, 4 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicator Value
52 Week High 68.55
52 Week Low 33.51
Average Volume 827,148
200-Day Moving Average 50.6839
50-Day Moving Average 47.6954
20-Day Moving Average 41.0955
10-Day Moving Average 36.175
Average True Range 2.17
ADX 44.39
+DI 9.7037
-DI 32.2945
Chandelier Exit (Long, 3 ATRs ) 42.78
Chandelier Exit (Short, 3 ATRs ) 40.02
Upper Bollinger Band 52.134
Lower Bollinger Band 30.057
Percent B (%b) 0.25
BandWidth 53.72121
MACD Line -3.8173
MACD Signal Line -3.5686
MACD Histogram -0.2487
Fundamentals Value
Market Cap 2.53 Billion
Num Shares 71.2 Million
EPS -1.92
Price-to-Earnings (P/E) Ratio -18.53
Price-to-Sales 32.73
Price-to-Book 16.72
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 36.62
Resistance 3 (R3) 36.64 36.32 36.44
Resistance 2 (R2) 36.32 36.05 36.31 36.38
Resistance 1 (R1) 35.95 35.89 36.13 35.92 36.33
Pivot Point 35.62 35.62 35.72 35.61 35.62
Support 1 (S1) 35.25 35.36 35.44 35.22 34.81
Support 2 (S2) 34.92 35.19 34.91 34.76
Support 3 (S3) 34.55 34.92 34.70
Support 4 (S4) 34.52